A Phase 2, randomized, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec-vncg (ADSTILADRIN) alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC).
A Phase 3b, randomized, controlled trial of nadofaragene firadenovec-vncg (ADSTILADRIN) vs. observation in subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
A Phase 4, multi-center, non-interventional study to collect data on the early use of nadofaragene firadenovec-vncg (ADSTILADRIN) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC), in a real-world setting. The study is exploring early utilization, experiences, and outcomes of ADSTILADRIN in a routine care setting.